Modulators of MYC and methods of using the same
Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.
1. A method of enhancing an immune response, comprising:
administering to an individual a fusion peptide before, during, or after administration of an antigenic moiety, wherein the fusion peptide comprises:
a. a transporter peptide sequence; and
b. a MYC polypeptide sequence,
wherein the transporter peptide sequence transports the fusion peptide into the nucleus of an immune cell in the individual.
2. The method of claim 1 , wherein the fusion peptide has Formula (I): transporter peptide sequence -MYC sequence.
3. The method of claim 1 , wherein the fusion peptide has Formula (II): transporter peptide sequence-X-MYC sequence,
wherein -X- is at least one molecule that links the transporter peptide sequence and the MYC sequence.
4. The method of claim 1 , wherein the fusion peptide has Formula (II): transporter peptide sequence-X-MYC sequence, wherein in X is at least one amino acid.
5. The method of claim 1 , wherein the fusion peptide comprises the following sequence (SEQ ID NO: 1):
MDFFRVVENQQPPATMPLNVSFTNRNYDLDYDSVQPYFYCDEEENFYQQQ
QQSELQPPAPSEDIWKKFELLPTPPLSPSRRSGLCSPSYVAVTPFSLRGD
NDGGGGSFSTADQLEMVTELLGGDMVNQSFICDPDDETFIKNIIIQDCMW
SGFSAAAKLVSEKLASYQAARKDSGSPNPARGHSVCSTSSLYLQDLSAAA
SECIDPSVVFPYPLNDSSSPKSCASQDSSAFSPSSDSLLSSTESSPQGSP
EPLVLHEETPPTTSSDSEEEQEDEEEIDVVSVEKRQAPGKRSESGSPSAG
GHSKPPHSPLVLKRCHVSTHQHNYAAPPSTRKDYPAAKRVKLDSVRVLRQ
ISNNRKCTSPRSSDTEENVKRRTHNVLERQRRNELKRSFFALRDQIPELE
NNEKAPKVVILKKATAYILSVQAEEQKLISEEDLLRKRREQLKHKLEQLR
KGELNSKLE.
6. The method of claim 1 , wherein the peptide has the following sequence (SEQ ID NO: 2):
MRKKRRQRRRMDFFRVVENQQPPATMPLNVSFTNRNYDLDYDSVQPY
FYCDEEENFYQQQQQSELQPPAPSEDIWKKFELLPTPPLSPSRRSGL
CSPSYVAVTPFSLRGDNDGGGGSFSTADQLEMVTELLGGDMVNQSFI
CDPDDETFIKNIIIQDCMWSGFSAAAKLVSEKLASYQAARKDSGSPN
PARGHSVCSTSSLYLQDLSAAASECIDPSVVFPYPLNDSSSPKSCAS
QDSSAFSPSSDSLLSSTESSPQGSPEPLVLHEETPPTTSSDSEEEQE
DEEEIDVVSVEKRQAPGKRSESGSPSAGGHSKPPHSPLVLKRCHVST
HQHNYAAPPSTRKDYPAAKRVKLDSVRVLRQISNNRKCTSPRSSDTE
ENVKRRTHNVLERQRRNELKRSFFALRDQIPELENNEKAPKVVILKK
ATAYILSVQAEEQKLISEEDLLRKRREQLKHKLEQLRKGELNSKLEG
KPIPNPLLGLDSTRTGHHHHHH.
7. The method of claim 1 , wherein the antigenic moiety is a pathogen or derived from a pathogen.
8. The method of claim 7 , wherein the pathogen is one or more pathogens selected from the group consisting of: hepatitis A; hepatitis B; polio; measles; mumps; rubella; diphtheria; pertussis; tetanus; influenza; varicella zoster virus; rotavirus; meningococcal; pneumonia; smallpox; cholera; bubonic plague; yellow fever; tuberculosis; and human papillomavirus.
9. The method of claim 1 , wherein the antigenic moiety is a neoplastic cell or derived from a neoplastic cell.
10. The method of claim 1 , wherein the fusion protein is administered after administration of an antigenic moiety.
11. The method of claim 1 , wherein the fusion protein is formulated for subcutaneous delivery.
12. The method of claim 1 , wherein the immune cell is a primary lymphocyte.